Market Cap
$3.9B
CPRX
CATALYST PHARMACEUTICALS, INC.
—
Market cap$3.9B
12-mo target$31.67 (+0.6%)
High Impact Filing (9/10)25 New Institutional Positions25 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on CPRX right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Inst. Holders
50 funds
Inst. Value
$2.6B
Inst. Activity
25 buys / 25 sells
SEC Reports
15
Price chart
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 22, 2026 SEC Jul 17, 2026 SEC
CPRX saw a mixed institutional cluster in Q2 2026: 23 buyers added $226.9M in new positions (led by JPMorgan, American C
INST-CLUSTER — Impact 5/10
Aug 12, 2026 earnings_calendar
Jul 24, 2026 SEC CPRX Q2 2026 Earnings Scheduled — 2026-08-12
Catalyst Pharmaceuticals filed a Form 15-12G to terminate its SEC registration under Section 12(g), effective July 24, 2
15-12G — Impact 9/10
Catalyst Pharmaceuticals received SEC effectiveness on July 16, 2026 for four separate shelf registration statements (Fi
EFFECT — Impact 5/10
Jul 15, 2026 Insider
DENKHAUS DONALD A disposed of 20,000 shares
Director
Jul 15, 2026 Insider
DENKHAUS DONALD A disposed of 498,773 shares
Director @ $31.50 ($15.7M)
Jul 15, 2026 Insider
DENKHAUS DONALD A disposed of 33,500 shares
Director
Jun 30, 2026 Inst.
AMERICAN CENTURY COMPANIES INC — ADD
5,553,921 shares ($174.6M)
Analyst ratings buy % -100.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| May 28, 2026 | HC Wainwright & Co. | DOWNGRADE | Neutral | 43% |
| May 8, 2026 | Citigroup | DOWNGRADE | Neutral | 55% |
| May 7, 2026 | Stephens & Co. | DOWNGRADE | Equal-Weight | 54% |
| Mar 3, 2026 | Citigroup | MAINTAIN | Buy | 55% |
| Nov 7, 2025 | Citigroup | MAINTAIN | Buy | 55% |
| Mar 3, 2025 | Baird | MAINTAIN | Outperform | 54% |
| Feb 28, 2025 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Feb 27, 2025 | Stephens & Co. | REITERATE | Overweight | 54% |
| Feb 4, 2025 | Baird | INITIATE | Outperform | 54% |
| Jan 10, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | 0 | 0 | 6 | 1 | 2 | 0% | |
| Jun 1, 2026 | 2 | 4 | 6 | 0 | 0 | 50% | |
| May 1, 2026 | 7 | 6 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 7 | 6 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 7 | 6 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 7 | 6 | 1 | 0 | 0 | 93% | |
| Jan 1, 2026 | 7 | 6 | 1 | 0 | 0 | 93% |
Price targets
Where 3 covering analysts think CPRX trades over the next 12 months.
$31.67 +0.6% upside Hold
Current$31.49 Low$31.50 Median$31.50 High$32.00 3 analysts
$31.50$32.00
Analyst rating None as of Sep 14, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
15 SEC filing reports analyzed · 6 bullish, 4 bearish, 1 mixed, 4 neutral · avg impact 6.5/10.
MIXEDINST-CLUSTER5/10
CPRX saw a mixed institutional cluster in Q2 2026: 23 buyers added $226.9M in new positions (led by
Aug 22, 2026
BEARISH15-12G9/10
Catalyst Pharmaceuticals filed a Form 15-12G to terminate its SEC registration under Section 12(g),
Jul 24, 2026
BEARISHEFFECT5/10
Catalyst Pharmaceuticals received SEC effectiveness on July 16, 2026 for four separate shelf registr
Jul 17, 2026
BEARISH25-NSE9/10
Nasdaq filed a Form 25-NSE to delist Catalyst Pharmaceuticals' common stock under Rule 12d2-2(a)(3),
Jul 15, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Aug 12, 2026
earnings_calendar
CPRX Q2 2026 Earnings Scheduled — 2026-08-12
Jul 16, 2026
listing_status
Delisted: CPRX — removed from the Nasdaq symbol directory
Catalyst Pharmaceuticals, Inc. - Common Stock
Jul 16, 2026
trading_halt
Halt Resumed: CPRX — trading resumed after D (Security Deletion)
Halted 2026-07-14T23:50:00.000Z | Resumed 2026-07-16T04:00:01.000Z
Jul 14, 2026
trading_halt
Trading Halt: CPRX — T12 (Additional Information Requested)
Catalyst Pharmaceuticals, Inc. | Market: NASDAQ | Code: T12 — Additional Information Requested
Jul 14, 2026
trading_halt
Trading Halt: CPRX — D (Security Deletion)
Catalyst Pharmaceuticals, Inc. | Market: NASDAQ | Code: D — Security Deletion
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.74 | $0.74–$0.74 | 8.2% | +6.3% | 1↑ 0↓ | $0.2B | 1 |
| Current FY | $3.17 | $3.17–$3.17 | 16.7% | +11.0% | 1↑ 0↓ | $0.6B | 1 |
| Next FY | $3.18 | $2.58–$3.55 | 0.2% | +1.5% | 1↑ 0↓ | $0.7B | 3 |
| Next Q | $0.82 | $0.82–$0.82 | 20.4% | +12.1% | 1↑ 0↓ | $0.2B | 1 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.736 | — |
| 7d ago | $0.692 | +0.043 |
| 30d ago | $0.692 | +0.043 |
| 60d ago | $0.675 | +0.061 |
| 90d ago | $0.675 | +0.061 |
Institutional ownership
Which big funds own CPRX (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $2.6B total value (81,323,191 shares) as of 2026-Q2. Top holders: BlackRock,, STATE, AMERICAN.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 19,158,785 | $602.2M | 23.6% | — |
| STATE STREET CORP | 7,627,036 | $239.7M | 9.4% | — |
| AMERICAN CENTURY COMPANIES INC | 5,553,921 | $174.6M | 6.8% | ADD +34.2% |
| VANGUARD CAPITAL MANAGEMENT LLC | 5,135,345 | $161.4M | 6.3% | — |
| DIMENSIONAL FUND ADVISORS LP | 3,634,171 | $114.2M | 4.5% | — |
| JPMORGAN CHASE & CO | 3,169,902 | $99.9M | 3.9% | DOUBLED +579.0% |
| GEODE CAPITAL MANAGEMENT, LLC | 3,150,256 | $99.0M | 3.9% | — |
| MORGAN STANLEY | 2,760,358 | $86.8M | 3.4% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2,428,922 | $76.3M | 3.0% | — |
| Jupiter Topco LLC | 2,277,822 | $71.6M | 2.8% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| AMERICAN CENTURY COMPANIES INC | ADD | 4,138,416 | 5,553,921 | +34.2% | $174.6M |
| JPMORGAN CHASE & CO | DOUBLED | 466,820 | 3,169,902 | +579.0% | $99.9M |
| Qube Research & Technologies Ltd | DOUBLED | 412,666 | 2,254,355 | +446.3% | $70.9M |
| UBS Group AG | ADD | 986,090 | 1,453,726 | +47.4% | $45.7M |
| BANK OF AMERICA CORP /DE/ | TRIM | 3,036,546 | 1,311,366 | -56.8% | $41.2M |
| MILLENNIUM MANAGEMENT LLC | ADD | 766,991 | 1,068,724 | +39.3% | $33.6M |
| MARSHALL WACE, LLP | DOUBLED | 201,815 | 911,700 | +351.8% | $28.7M |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | NEW | — | 795,700 | — | $25.0M |
| Swedbank AB | ADD | 616,132 | 775,032 | +25.8% | $24.4M |
| FIL Ltd | NEW | — | 650,000 | — | $20.4M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
7 insiders, 50 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 15, 2026 | DENKHAUS DONALD A | Director | D | 20,000 | — | — |
| Jul 15, 2026 | DENKHAUS DONALD A | Director | D | 498,773 | $31.50 | $15.7M |
| Jul 15, 2026 | DENKHAUS DONALD A | Director | D | 33,500 | — | — |
| Jul 15, 2026 | DENKHAUS DONALD A | Director | D | 15,000 | — | — |
| Jul 15, 2026 | DENKHAUS DONALD A | Director | D | 23,248 | — | — |
| Jul 15, 2026 | Tierney David S | Director | D | 33,500 | — | — |
| Jul 15, 2026 | Tierney David S | Director | D | 18,115 | — | — |
| Jul 15, 2026 | DENKHAUS DONALD A | Director | D | 30,000 | — | — |
| Jul 15, 2026 | DENKHAUS DONALD A | Director | D | 29,524 | — | — |
| Jul 15, 2026 | DENKHAUS DONALD A | Director | D | 18,115 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for CPRX.
Shares short
340,264
Settlement Jul 15, 2026
Change vs prior
-95.7%
Semi-monthly cycle
Days to cover
1.0
At avg daily volume
Of shares outstanding
≈0.3%
Estimate — not % of float
| Halted | Code | Reason | Status |
|---|---|---|---|
| Jul 14, 2026 | T12 | Info Requested | Not resumed |
| Jul 14, 2026 | D | Deletion | Resumed |
All CPRX filing & press-release reports (15)
- INST-CLUSTER reportAug 22, 2026
- 15-12G reportJul 24, 2026
- EFFECT reportJul 17, 2026
- 25-NSE reportJul 15, 2026
- 8-K reportJul 8, 2026
- 8-K reportJul 3, 2026
- DEFA14A reportJun 30, 2026
- PREM14A reportMay 28, 2026
- DEFA14A reportMay 12, 2026
- PRESS-RELEASE reportMay 11, 2026
- DEFA14A reportMay 7, 2026
- DEFA14A reportMay 7, 2026
- 8-K reportMay 7, 2026
- 8-K/A reportMar 19, 2026
- 8-K reportFeb 25, 2026